Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis

BACKGROUND. The randomized phase III RAINBOW trial established paclitaxel (pac) plus ramucirumab (ram) as a global standard for second‐line (2L) therapy in advanced gastric and gastroesophageal junction adenocarcinoma, together gastroesophageal adenocarcinoma (GEA). Patients (pts) receiving first‐li...

Descripción completa

Detalles Bibliográficos
Autores principales: Klempner, Samuel J., Maron, Steven B., Chase, Leah, Lomnicki, Samantha, Wainberg, Zev A., Catenacci, Daniel V.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459251/
https://www.ncbi.nlm.nih.gov/pubmed/30470690
http://dx.doi.org/10.1634/theoncologist.2018-0602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459251/
https://www.ncbi.nlm.nih.gov/pubmed/30470690
http://dx.doi.org/10.1634/theoncologist.2018-0602

Ejemplares similares